LenioBio

Dusseldorf, Germany Founded: 2016 • Age: 10 yrs
Kits for cell-free eukaryotic protein expression are provided.
Annual revenue - Latest available
Total funding $13.0M 7 rounds
Employees 18 Tracked headcount
Investors 6 Known backers
Products 3 Services tracked
Competitors 9 Brand Intelligence

About LenioBio

LenioBio is a company based in Dusseldorf (Germany) founded in 2016 by Remberto Martis and Hakon Birgisson. LenioBio has raised $13.01 million across 7 funding rounds from investors including EIT Food, European Union and Eureka Network. The company has 18 employees as of December 31, 2020. LenioBio offers products and services including ALiCE® Products, ALiCE® as a Service, and ALiCE® for High-Throughput Expression. LenioBio operates in a competitive market with competitors including PrognomiQ, PreOmics, Vivostat, ACRO Biosystems and List Biological Laboratories, among others.

  • Headquarter Dusseldorf, Germany
  • Employees 18 as on 31 Dec, 2020
  • Founders Remberto Martis, Hakon Birgisson
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Leniobio Gmbh
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $13.01 M (USD)

    in 7 rounds

  • Latest Funding Round
    $4.33 M (USD), Grant

    Jul 23, 2025

  • Investors
    EIT Food

    & 5 more

  • Employee Count
    18

    as on Dec 31, 2020

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of LenioBio

LenioBio offers a comprehensive portfolio of products and services, including ALiCE® Products, ALiCE® as a Service, and ALiCE® for High-Throughput Expression.

Product name locked
Category locked
Primary

Enables rapid and scalable protein production for research.

Product name locked
Category locked
Locked

Offers expert services for challenging protein targets.

Product name locked
Category locked
Locked

Facilitates efficient protein expression in high-throughput setups.

People of LenioBio

Headcount 10-50
Employee Profiles 17
Employee Profiles
People
Alexander Dahlmanns, LL.M.
General Counsel
People
Robin Roentgen
Head Of Technical Development
People
Maja Lieven (née Rennig)
Team Lead Production
People
Charles Williams
Lead Strategic Projects

Unlock access to complete

Funding Insights of LenioBio

LenioBio has successfully raised a total of $13.01M across 7 strategic funding rounds. The most recent funding activity was a Grant round of $4.33 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in LenioBio

LenioBio has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include EIT Food, European Union and Eureka Network.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Government agency and accelerator focusing on innovative startups and SMEs
Locked Locked Locked
Early-stage tech companies are invested in by Bridford Group.
Locked Locked Locked
Food safety testing services are provided by EIT Food.
Locked Locked Locked
Premium access

Investor details for LenioBio

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by LenioBio

Investments
Premium access

Investment portfolio details for LenioBio

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - LenioBio

Premium access

Detailed financials for LenioBio

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Leniobio Comparisons

LenioBio Primary company
Description
Kits for cell-free eukaryotic protein expression are provide...
Location
Dusseldorf, Germany
Founded Year
2016
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
18
As of 2020
Premium access

Peer comparison for LenioBio

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of LenioBio

LenioBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PrognomiQ, PreOmics, Vivostat, ACRO Biosystems and List Biological Laboratories, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Developer of tests for the detection and treatment of cancer and other diseases
Locked Locked Locked
Reagents and instruments for proteomics research are supplied by PreOmics.
Locked Locked Locked
On-site fibrin sealant preparation systems are developed and provided.
Locked Locked Locked
Recombinant proteins are manufactured to support cancer immunotherapy efforts.
Locked Locked Locked
Specializes in the production of research reagents
Premium access

Detailed competitors of LenioBio

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Leniobio

Premium access

Complete news archive for LenioBio

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about LenioBio

LenioBio was founded in 2016 and raised its 1st funding round 3 years after it was founded.

LenioBio is headquartered in Dusseldorf, Germany. It is registered at Dusseldorf, North Rhine-westphalia, Germany.

Remberto Martis is the current CEO of LenioBio. They have also founded this company.

LenioBio is a funded company, having raised a total of $13.01M across 7 funding rounds to date.

As of Dec 31, 2020, the latest employee count at LenioBio is 18.

LenioBio was founded in 2016 in Dusseldorf, Germany, and operates in the biotechnology sector. Cell-free protein expression kits are developed and supplied, with the ALiCE platform serving as the primary eukaryotic system for handling difficult-to-express proteins. Active energy regeneration is incorporated, along with essential components for protein folding, disulfide bonding, and glycosylation, supporting discovery, development, and production processes.

LenioBio's top competitors include PrognomiQ, Vivostat and PreOmics.

LenioBio offers ALiCE® Products, ALiCE® as a Service, and ALiCE® for High-Throughput Expression.

LenioBio has 6 investors. Key investors include EIT Food, European Union, Eureka Network, EIC Fund, and Bridford Group.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available